Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors

US6858409B1 · kind B1 · utility

Assignees

• AMGEN INC. · US
• The Regents of the University of Colorado · US

Inventors

• Robert C. Thompson · Boulder, US
• Charles H. Hannum · Sunnyvale, US
• Stephen P. Eisenberg · Boulder, US
• William P. Arend · Denver, US
• Fenneke G. Joslin · Denver, US
• Andreas Sommer · North Wales, US

Key dates

• Filing date: Jun 7, 1995
• Grant date: Feb 22, 2005
• Expiry date: Jun 7, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds are disclosed having the general formula R1—X—R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.